The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Hims & Hers Health HIMS-6.01%decrease ... green up pointing triangle & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers ...

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic ...

BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

The selloff followed Hims & Hers’ announcement that it had added Eli Lilly’s (LLY) popular weight-loss drug Zepbound and a generic ... HIMS’ liraglutide launch will be relevant over the ...

Investor excitement about news of a fresh product launch ... Zepbound. It's also gearing up to sell biosimilars of Novo Nordisk diabetes treatment liraglutide. Investors plowed into Hims & Hers ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers.